Laws and sections by number or title, due dates, pages, and updates.
The Employees' State Insurance Corporation has issued a downward rate revision for Item No. 2128 (Ibrutinib 140mg) under DGESIC Rate Contract 161, supplied by M/s. Johnson & Johnson Pvt. Ltd. The rate has been reduced from Rs. 1,557.39 per capsule to Rs. 1,448.69 per capsule, effective from April 8, 2026. Drawing and Disbursing Officers (DDOs) are required to recover the difference in rates for any supply orders placed on or after this date from subsequent bills submitted by the firm. The responsibility for reconciliation and recovery rests with the competent authorities and DDOs of the respective institutes.
What you must do
Key dates
Who is affected
Thresholds
If you do not comply
Ask about this circular
HEADQUARTERS EMPLOYEES' STATE INSURANCE CORPORATION (Ministry of Labour & Employment, Govt. of India) Panchdeep Bhawan, C.I.G. Marg, New Delhi-110002
U-25/12/159-164/Amend-Price/2025/Med.V (E:1222663)/211 Dt.: Signed Date
To, Director (Medical) Delhi/Director (Medical) NOIDA Dean, All ESIC PGIMSR's, Medical & Dental Colleges Medical Superintendents-All ESIC Hospitals Director, ESI Scheme-All States
Amendment - 17 /2026
Sub: Downward Rate Revision for Item No. 2128 under DGESIC RC-161 of approved pharmaceutical firm M/s Johnson & Johnson Pvt. Ltd - reg
Ref.: U-25/12/159to163/2022-Med.V(E-117064) wef 08.04.2025 to 07.04.2027
Sir/Madam,
The following amendment of Downward Rate Revision in r/o Item no. 2128 in RC161 of M/s. Johnson & Johnson Pvt. Ltd may please be noted:
| RC No | Item No | Item Name and Description in DGESIC RC 161 | Existing Rate | Amended/ Revised Rate wef. 08.04.2026 | Recovery / Difference of rates (If any) |
|---|---|---|---|---|---|
| 161 | 2128 | Ibrutinib Tab/Cap- Each Cap/Tab to contain: Ibrutinib 140mg. Brand Name: Imbruvica ® Packing: Bottle of 90 Capsules GST @5% Extra | Rs.1,557.39 per Cap | Rs. 1,448.69 per Cap | Difference in rates to be deducted for supply orders placed wef 8th April 2026, if any |
The said amendment has been issued on the request of the firm- M/s. Johnson & Johnson Pvt. Ltd
The drugs shall continue to adhere to composition, strength, standards and packing as approved under the respective DGESIC Rate Contract & conform to the standards and specifications as per the Drug & Cosmetic Act and/or any amendments thereof.
All DDOs are advised to recover the excess amount paid to the firm (i.e. difference in rates to be deducted for the Supply orders placed on/after 08.04.2026) from their subsequent bills submitted by the firms and maintain records of the same.
Reconciliation / recovery under the said amendment is the sole responsibility of the Competent Authority / DDOs of the respective institutes.
Digitally signed by Sanjiv Kochhar Date: 06-08-2026 11:18:25
(Sanjiv Kochhar) Director (Med.)
Copy for information to:
